QT prolongation refers to an abnormally long QT interval on an electrocardiogram (ECG), meaning the heart takes longer than normal to electrically reset after each beat. This delay can trigger life-threatening arrhythmias, including torsades de pointes and sudden cardiac death, and can be present from birth as a genetic condition or acquired through medications, electrolyte disturbances, or underlying disease. In many cases, it is both detectable and manageable with the right clinical approach.
Related: What Does White Blood Cells in Urine Mean and When Should You Act?
What Is QT Prolongation?
QT prolongation refers to an abnormally long QT interval on an electrocardiogram — the portion of the heart's electrical trace that captures the time between ventricular depolarisation (the electrical firing of the lower heart chambers) and repolarisation (the reset phase). Think of the QT interval like the time it takes a stretched rubber band to return to its resting shape. If that return is too slow, the heart remains in an electrically vulnerable state, susceptible to abnormal triggers that can initiate dangerous arrhythmias.
The condition can be congenital or acquired through drugs, electrolyte abnormalities, or disease. When the QT interval is sufficiently prolonged, the most feared consequence is torsades de pointes, a form of ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death.
Clinicians use a heart-rate-corrected value called the QTc to standardise measurement. A QTc exceeding 440ms in men or 460ms in women is generally considered prolonged. Values above 500ms, regardless of sex, carry the highest arrhythmic risk. Understanding what this means and why it matters is the foundation for everything that follows.
Understanding the QT Interval: A Visual Guide
The standard ECG trace follows a characteristic PQRST waveform pattern, with each letter representing a distinct electrical event in the cardiac cycle.
The P wave: reflects atrial depolarisation.
The QRS complex: represents ventricular depolarisation (the rapid electrical firing of the lower chambers that triggers contraction).
The T wave: represents ventricular repolarisation, the phase in which the ventricles electrically reset in preparation for the next beat.
The QT interval is measured from the beginning of the Q wave to the end of the T wave. This entire window captures the time the ventricles spend in the active electrical phase. The end of the T wave is particularly important: during repolarisation, the myocardium has variable excitability across different cells, creating a window in which an abnormal electrical impulse, known as an early afterdepolarisation, can ignite torsades de pointes.
Because heart rate directly affects the raw QT measurement (a faster rate shortens it, a slower rate lengthens it), clinicians apply a correction formula to produce a rate-independent value. A faster heart rate naturally shortens the QT interval, so doctors apply a correction formula to make the measurement meaningful regardless of how fast or slow the heart is beating.
Types of Long QT Syndrome: Congenital vs Acquired
Long QT syndrome (LQTS) divides into two fundamentally different categories based on cause, each with distinct implications for management.
Congenital long QT syndrome is a genetic condition caused by mutations in genes encoding cardiac ion channels. It affects approximately 1 in 2,000 people and represents faulty electrical wiring present from birth. The three most common subtypes — LQT1, LQT2, and LQT3 — each carry characteristic triggers and risk profiles. The most common inherited form is Romano-Ward syndrome, which follows an autosomal dominant pattern. A rarer, more severe form, Jervell and Lange-Nielsen syndrome, is autosomal recessive and associated with congenital sensorineural deafness.
Acquired long QT syndrome is considerably more common in clinical practice. It arises from external factors rather than genetic predisposition and is often fully reversible once the cause is removed. The primary causes include medications, electrolyte disturbances (particularly low potassium and magnesium), bradycardia, structural heart disease, and conditions such as hypothyroidism.
The clinical distinction matters: congenital LQTS requires lifelong management, while acquired QT prolongation can frequently be resolved by addressing its cause.
Congenital LQTS: Genetic Subtypes and Their Triggers
The three most prevalent genetic subtypes reflect defects in specific ion channels responsible for cardiac repolarisation. LQT1, caused by mutations in the KCNQ1 gene affecting the IKs potassium channel, is most commonly triggered by exercise — particularly swimming — and accounts for the majority of events. LQT2, caused by KCNH2 mutations affecting the IKr channel, is characteristically triggered by sudden auditory stimuli such as an alarm or telephone ringing. LQT3, caused by SCN5A mutations producing a persistent inward sodium current, tends to cause events during rest or sleep. Understanding these triggers directly informs both lifestyle advice and risk stratification.
Acquired QT Prolongation: What External Factors Are Responsible
The main categories of acquired QT prolongation include drugs (the most common cause — discussed in detail below), electrolyte disturbances including hypokalaemia, hypomagnesaemia, and hypocalcaemia, structural heart disease such as heart failure and post-myocardial infarction remodelling, bradycardia from any cause, and systemic conditions such as hypothyroidism and liver failure. Because acquired QT prolongation is reversible in most cases, accurate identification of the causative factor is both diagnostically and therapeutically essential.
Drug-Induced QT Prolongation: The Medicines Most Commonly Involved
Drug-induced QT prolongation is the most clinically encountered form of acquired QT prolongation and has been the leading reason for post-market drug withdrawals over the past three decades. It occurs across a wide range of drug classes, many of which have no primary cardiac indication.
The common pharmacological mechanism is blockade of the hERG potassium channel (encoding the IKr current), which is the dominant current responsible for ventricular repolarisation. The hERG channel has an unusually large binding cavity that makes it susceptible to a diverse array of drug structures, meaning even medications targeting entirely different organ systems can inadvertently block it and extend the QT interval.
Key drug classes and examples include:
- Antiarrhythmics: Amiodarone, sotalol, and quinidine all carry significant QT risk — a paradox given they are used to treat arrhythmias.
- Antibiotics: Azithromycin and clarithromycin carry well-established risk. The fluoroquinolones — ciprofloxacin, levofloxacin, and moxifloxacin — are widely prescribed and frequently overlooked as QT risks.
- Antipsychotics: Haloperidol, quetiapine, and ziprasidone all carry QT-prolonging potential, of particular relevance in mental health and care home settings.
- Antidepressants: Citalopram and escitalopram are associated with dose-dependent QT prolongation. The FDA issued a specific warning restricting citalopram doses to 40mg/day (20mg in patients over 60 or with hepatic impairment) following evidence of QT prolongation at higher doses.
- Antihistamines: Terfenadine and astemizole, once widely used, were withdrawn from the market primarily because of fatal torsades de pointes.
- Antimalarials: Chloroquine and hydroxychloroquine gained significant public attention during the COVID-19 pandemic for this reason.
The CredibleMeds / AZCERT system provides a free, evidence-based drug classification database, categorising agents into Known Risk, Conditional Risk, and Possible Risk categories — an essential reference for prescribers and pharmacists. QT risk is additive: combining two or more QT-prolonging agents substantially increases risk beyond what either drug would produce alone.
How Drug-Drug Interactions Amplify QT Risk
The risk compounds through two mechanisms. The first is pharmacodynamic: combining two hERG-blocking agents creates additive QT prolongation. A patient stabilised on an antipsychotic, for example, may tip into dangerous territory if prescribed azithromycin for a respiratory infection — a common clinical scenario that can pass unnoticed without structured interaction checking.
The second mechanism is pharmacokinetic: CYP450 enzyme inhibition can elevate plasma concentrations of QT-prolonging drugs. Clarithromycin inhibits CYP3A4, raising levels of co-administered drugs metabolised by the same pathway, potentially transforming a safe dose into a dangerous one. This reinforces why a comprehensive drug interaction review at the point of prescribing and dispensing is not optional — it is a clinical safeguard.
Symptoms of Long QT Syndrome
Many people with QT prolongation — particularly those with congenital LQTS — have no symptoms at all. The condition is frequently identified incidentally, during a routine ECG for an unrelated purpose or through family cardiac screening following a relative's diagnosis.
When symptoms do occur, they reflect the haemodynamic consequences of arrhythmia. The recognised spectrum includes:
- Palpitations or the sensation of a racing or irregular heartbeat
- Dizziness or lightheadedness, typically sudden in onset
- Syncope (fainting), often triggered by the specific stimuli characteristic of each LQTS subtype — exercise in LQT1, sudden noise in LQT2
- Seizure-like episodes caused by brief cerebral hypoperfusion during a transient arrhythmia — these are frequently misattributed to epilepsy, significantly delaying the correct diagnosis
- Sudden cardiac arrest — in the most severe and undetected cases, this may be the first clinical presentation
The risk of misdiagnosis deserves particular emphasis. A young person presenting with unexplained fainting or seizure-like episodes is not always referred for cardiac evaluation. LQTS should be actively considered in any young patient with unexplained syncope, particularly if triggered by exercise or emotional stress, or in any patient with a family history of sudden unexplained cardiac death in a young relative. These constitute red flag presentations requiring urgent specialist assessment.
Risk Factors That Make QT Prolongation More Likely
Specific patient characteristics significantly increase the probability of developing QT prolongation, whether congenital or acquired.
Genetic and family history: Factors include a known family history of LQTS, a confirmed ion channel gene mutation, or sudden unexplained cardiac death in a young first-degree relative — a history that should prompt immediate investigation.
Biological sex: Females have a naturally longer baseline QTc than males, and are two to three times more likely to develop drug-induced torsades de pointes for equivalent drug exposure. This sex-based vulnerability is particularly relevant when prescribing QT-prolonging medications to women.
Age: Age increases risk through mechanisms including polypharmacy, declining renal and hepatic drug clearance, and higher background rates of cardiac disease.
Electrolyte disturbances: Hypokalaemia is the most clinically significant: low potassium reduces the driving force for the IKr current and dramatically prolongs the QT interval. Hypomagnesaemia and hypocalcaemia compound this risk. Patients at risk of electrolyte depletion — through diuretic use, poor nutrition, or gastrointestinal illness — warrant close monitoring.
Cardiac conditions: heart failure, bradycardia, and prior myocardial infarction all reduce repolarisation reserve. Other relevant conditions include hypothyroidism, anorexia nervosa, and liver failure. Polypharmacy creates cumulative additive risk in patients managed across multiple specialties, particularly in elderly patients in care home settings.
How Is Long QT Syndrome Diagnosed?
Long QT syndrome is diagnosed through a structured clinical pathway that integrates ECG findings, clinical history, and increasingly, genetic data.
The 12-lead ECG remains the cornerstone investigation. Clinicians measure the QTc and apply standard thresholds (>440ms for men, >460ms for women) to identify prolongation. A single normal ECG does not exclude congenital LQTS, however — QTc can fluctuate, and some confirmed LQTS patients have borderline values at rest. Repeat ECGs across different time points increase diagnostic sensitivity. Exercise stress testing is particularly valuable for LQT1, where QTc paradoxically fails to shorten appropriately with increasing heart rate. Holter monitoring over 24–48 hours captures intermittent arrhythmias and QT fluctuations that a resting ECG would miss.
Genetic testing is recommended for all patients with a clinical LQTS diagnosis. It identifies a causative mutation in approximately 75% of confirmed cases and is indispensable for cascade screening of family members. Electrolyte blood tests are mandatory in all cases, both to identify reversible acquired causes and because hypokalaemia can confound QT measurements. Comprehensive medication review is equally essential — every drug the patient takes must be assessed for QT-prolonging potential.
Family screening of first-degree relatives should include ECG and, where a mutation is identified, targeted genetic testing. The Schwartz score — a validated diagnostic tool incorporating QTc value, clinical history, symptoms, and family history — helps clinicians synthesise this data into a formal diagnostic probability, reducing misclassification.
Treatment and Management of Long QT Syndrome
Treatment for QT prolongation is tailored to whether the condition is congenital or acquired, and to individual risk level.
Lifestyle modifications are the first pillar for congenital LQTS. Patients with LQT1 are typically advised to avoid competitive sport and unsupervised swimming. LQT2 patients should minimise exposure to sudden auditory triggers. Medical alert identification is recommended universally.
Beta-blockers — primarily nadolol or propranolol — are the pharmacological cornerstone of congenital LQTS management. They reduce adrenergically triggered arrhythmias and are most effective in LQT1. Beta-blocker compliance is a major determinant of long-term prognosis.
Electrolyte correction is both a treatment and a preventive measure. Adequate potassium and magnesium intake should be maintained, with supplementation prescribed where there is documented deficiency. Medication review and drug avoidance are essential — patients should carry a personalised list of QT-prolonging drugs to avoid and check with their pharmacist before starting any new medication, including over-the-counter products.
Implantable cardioverter-defibrillator (ICD) placement is recommended for high-risk patients: survivors of cardiac arrest, those with refractory symptoms despite beta-blocker therapy, and certain genotype-specific high-risk presentations. Left cardiac sympathetic denervation (LCSD) is a surgical option for patients unable to tolerate beta-blockers or who continue to have events on maximum medical therapy.
For acquired QT prolongation, the primary treatment is cause removal: stop the offending drug, correct electrolytes, treat the underlying medical condition. The QT interval typically normalises once the precipitant is resolved.
|
Treatment |
Indication |
First-line? |
Key Notes |
|
Beta-blockers (nadolol/propranolol) |
Congenital LQTS |
Yes |
Most effective in LQT1; compliance critical |
|
ICD |
High-risk congenital LQTS; post-arrest |
Selected patients |
Safety net; does not prevent arrhythmia |
|
LCSD (sympathetic denervation) |
Refractory LQTS; beta-blocker intolerance |
Third-line |
Surgical; reduces adrenergic triggers |
|
Electrolyte correction |
Acquired; congenital adjunct |
Yes (acquired) |
Potassium and magnesium targets |
|
Drug withdrawal |
Acquired (drug-induced) |
Yes |
QT typically normalises on cessation |
|
Lifestyle modification |
All LQTS patients |
Yes (adjunct) |
Subtype-specific trigger avoidance |
Acute Management of Torsades de Pointes
When QT prolongation degenerates into torsades de pointes, immediate intervention is required. Intravenous magnesium sulphate is the first-line treatment, stabilising the cardiac membrane and terminating the arrhythmia in most cases. If the arrhythmia is bradycardia-related, temporary pacing may be required to increase heart rate and shorten the QT interval. Defibrillation is necessary if torsades deteriorates into ventricular fibrillation. Any causative drug must be discontinued immediately and electrolyte abnormalities corrected urgently. Standard antiarrhythmic agents such as amiodarone are generally contraindicated in this context, as they themselves prolong the QT interval and risk worsening the situation.
QT Prolongation Screening in Clinical Practice: A Gap Most Sources Miss
QT prolongation is systematically under-recognised in clinical practice — particularly in primary care, mental health settings, and care homes where polypharmacy is common and ECG monitoring is inconsistent.
One pharmacy group operating across multiple sites and an online prescribing channel identified this gap directly: without standardised QT risk screening protocols applied consistently across every dispensing touchpoint — not just in-person consultations — patients receiving QT-prolonging prescriptions through the online channel were not receiving the same structured interaction checks as those seen face to face. This kind of clinical governance disparity is not unusual, and it illustrates precisely why systematic protocols must be embedded at every dispensing level, regardless of channel.
Who should be proactively screened: Patients starting a QT-prolonging drug should have a baseline ECG and potassium level documented before the drug is issued. Patients already on multiple QT-prolonging agents require periodic ECG review. High-risk groups — elderly patients, women, those with cardiac disease or known electrolyte instability — warrant heightened vigilance.
Pre-prescription clinical checklist: Before issuing a QT-prolonging drug, prescribers and pharmacists should verify the current QTc, current serum potassium, a full drug interaction screen, and any personal or family history suggestive of congenital LQTS.
The pharmacist's role: Pharmacists are the last safety checkpoint before a drug reaches the patient. This applies equally to physical and online dispensing. Online prescription services must implement robust, structured clinical governance systems — every prescription request should pass through an explicit drug interaction and contraindication check before approval.
CredibleMeds AZCERT classifies drugs by QT risk level ('Known Risk', 'Conditional Risk', 'Possible Risk') and is freely available to clinicians and pharmacists as a real-time reference. Alert fatigue is a well-documented barrier in electronic prescribing systems — many clinicians override QT-prolongation alerts because of high alert volume. Systems that tier alerts by severity and require active acknowledgement for the highest-risk combinations perform better than blanket alerting.
Practical Steps for Patients on QT-Prolonging Medications
Patients have an active role in their own safety. Inform every prescriber and pharmacist about all current medications. Before starting any new treatment, including over-the-counter products, ask the pharmacist explicitly to check for QT-prolongation interactions. Avoid grapefruit and grapefruit juice, which inhibits CYP3A4 and can raise plasma levels of several QT-prolonging drugs. Report any palpitations, dizziness, or unexplained fainting to a clinician without delay. Carry a written or digital list of drug classes to avoid, and seek emergency care immediately for sustained palpitations or loss of consciousness.
Living With Long QT Syndrome: Prognosis and Outlook
For the majority of people with correctly diagnosed and well-managed congenital LQTS, the prognosis is genuinely good. With appropriate treatment, the risk of sudden cardiac death is substantially reduced, and most patients live full, normal-length lives.
Beta-blocker compliance is the single most important modifiable prognostic factor in congenital LQTS. Patients who take their medication consistently experience significantly fewer breakthrough arrhythmias. For those at highest risk — including survivors of cardiac arrest or those with particularly high-risk genetic variants — an ICD provides an additional safety net that can deliver life-saving defibrillation automatically.
Long-term monitoring is a permanent requirement. Regular ECG checks, annual cardiology review, and ongoing medication management ensure that treatment remains optimised as circumstances change. Activity restrictions are typically confined to competitive sport and high-intensity exercise; moderate physical activity is generally permitted with appropriate medical guidance.
The psychological impact of an LQTS diagnosis should not be minimised, particularly in young people and their families. Access to cardiac psychology support helps patients adjust and maintain quality of life. Because LQTS is an inherited condition, a new diagnosis has direct implications for the entire biological family — first-degree relatives should be offered ECG screening and, where a specific mutation has been identified, targeted genetic testing.
For acquired QT prolongation, the prognosis following correct identification and cause removal is excellent. The QT interval normalises, and no ongoing cardiac treatment is typically required.
According to the CDC, the age-adjusted death rate decreased 3.8% in 2024, underscoring how monitoring and managing cardiac risk factors like QT prolongation can contribute to improved survival outcomes. While sudden cardiac death remains a significant contributor to overall cardiovascular mortality, LQTS-related sudden death is — in the overwhelming majority of cases — a preventable outcome when the condition is detected and managed appropriately.
|
Patient Group |
Primary Management |
Monitoring Requirement |
Activity Guidance |
|
Congenital LQTS (low-risk) |
Beta-blockers + lifestyle |
Annual ECG; cardiology review |
Avoid competitive sport; moderate exercise permitted |
|
Congenital LQTS (high-risk) |
Beta-blockers + ICD |
Regular device check; ECG monitoring |
Individualised by cardiologist |
|
Acquired QT prolongation |
Remove cause; correct electrolytes |
Repeat ECG post-resolution |
No restriction once resolved |
|
Asymptomatic incidental finding |
Full risk stratification |
Repeat ECG; electrolytes; drug review |
Pending specialist assessment |
|
Family member of LQTS patient |
Screening ECG ± genetic testing |
Per specialist guidance |
Pending results |
If you have been told you have a prolonged QT interval, or if you are concerned about a medication you have been prescribed, speak to your pharmacist or GP. A pharmacist — whether in a physical pharmacy or through an online prescribing service — can review your full medication list and check for QT-prolongation risks before you start a new treatment.
Reducing QT Prolongation Risk with Expert Guidance
QT prolongation can range from a harmless ECG finding to a serious cardiac risk—but the good news is that with early detection, proper treatment, and careful medication management, QT prolongation is highly manageable. Whether it’s caused by genetics, medications, or electrolyte imbalances, the key is to identify risks early, correct what you can, and stay consistent with clinical monitoring. That’s where our expert support makes all the difference.
At MedsRUs, our online pharmacy services are designed to help you stay one step ahead, offering convenient access to medication reviews, prescription delivery, and guidance to reduce your risk of QT prolongation. If you’re taking medications that may impact heart rhythm or want peace of mind about your treatment plan, connect with MedsRUs today for fast, reliable, and professional care from wherever you are.